Document is current
Any future updates will be listed below
-
Authors
Nuqui, Xandra https://orcid.org/0000-0001-9615-8918
Casalino, Lorenzo https://orcid.org/0000-0003-3581-1148
Zhou, Ling https://orcid.org/0000-0003-3402-5719
Shehata, Mohamed
Wang, Albert https://orcid.org/0000-0003-1162-6837
Tse, Alexandra L. https://orcid.org/0000-0002-1629-6526
Ojha, Anupam A.
Kearns, Fiona L.
Rosenfeld, Mia A.
Miller, Emily Happy
Acreman, Cory M.
Ahn, Surl-Hee https://orcid.org/0000-0002-3422-805X
Chandran, Kartik
McLellan, Jason S. https://orcid.org/0000-0003-3991-542X
Amaro, Rommie E. https://orcid.org/0000-0002-9275-9553
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-031624)
Welch Foundation (F-0003-19620604)
- License Information
-
More Information
Article History
Received: 15 November 2023
Accepted: 25 July 2024
First Online: 27 August 2024
Competing interests
: J.S.M., L.Z., R.E.A., X.N., L.C., and M.S. are inventors on a U.S. patent application describing the use of stabilized SARS-CoV-2 S proteins as vaccine antigens (Stabilized SARS-CoV-2 S Antigens, 63/583,090). K.C. is a member of the scientific advisory board of Integrum Scientific LLC and has consulted for Axon Advisors, LLC. K.C. owns shares in Integrum Scientific and Eitr Biologics, Inc. The other authors declare no competing interests.
